Hi Dew..catching up on some posts that were started with my question on where is a decent PARS board. My question to you is, what will be your impression/recommendation/investment of GENR if it (or partner) does NOT seek and obtain Special Protocol Assessment as they further the trials with Squalamine? Are you saying the only way you are interested in investing in a biotech is only when they have received SPA? Thanks in advance for any reply. ciciagt